within Pharmacolibrary.Drugs.ATC.J;

model J01XA04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 8.333333333333333e-07,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.010199999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.008199999999999999,
    k12             = 0.036,
    k21             = 0.036
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01XA04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity primarily against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and is administered as an intravenous infusion.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are based on data from healthy adult volunteers receiving intravenous dalbavancin. Most studies use a two-compartment model.</p><h4>References</h4><ol><li><p>Van Matre, ET, et al., &amp; Kiser, TH (2020). Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients. <i>Antimicrobial agents and chemotherapy</i> 64(5) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.02089-19&quot;>10.1128/AAC.02089-19</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32122898/&quot;>https://pubmed.ncbi.nlm.nih.gov/32122898</a></p></li><li><p>Dash, RP, et al., &amp; Srinivas, NR (2017). Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. <i>Infectious diseases (London, England)</i> 49(7) 483–492. DOI:<a href=&quot;https://doi.org/10.1080/23744235.2017.1296968&quot;>10.1080/23744235.2017.1296968</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28264598/&quot;>https://pubmed.ncbi.nlm.nih.gov/28264598</a></p></li><li><p>Anderson, VR, &amp; Keating, GM (2008). Dalbavancin. <i>Drugs</i> 68(5) 639–651. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200868050-00006&quot;>10.2165/00003495-200868050-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18370443/&quot;>https://pubmed.ncbi.nlm.nih.gov/18370443</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01XA04;
